The new drug pricing policy empowers innovation, overseas authorization accelerates the double-wheel drive of the industry.

Recently, the State Council General Office issued "Several Opinions on Improving the Mechanism for Drug Price Formation", providing top-level design for empowering pharmaceutical innovation. At the same time, Chinese innovative drugs are continuously being authorized overseas, with multiple collaborations taking place. Recently, Hisun Pharma and American AbbVie signed an exclusive licensing agreement with a total transaction amount of up to $745 million. Since the beginning of 2026, many domestic pharmaceutical companies such as CSPC Pharma and Innovent Biologics have successively reached overseas authorization collaborations with multinational giants, with transactions intensifying and amounts continuously rising. Industry insiders believe that the peak sales expectations of domestic innovative drugs will be boosted, greatly stimulating business enthusiasm. The entire industry is evolving from being driven by overseas expansion to being driven by both domestic and international markets, further enhancing the industry's prosperity and certainty. On one hand, this will optimize the profit space of various links in the domestic innovative drug industry chain, and on the other hand, it will further boost the demand for domestic innovative drug research and development.